1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Zhejiang Xinguang Pharmaceutical Co., Ltd.

Zhejiang Xinguang Pharmaceutical Co., Ltd.

300519.SZ
Zhejiang Xinguang Pharmaceutical Co., Ltd.CN flagShenzhen Stock Exchange
12.92
CNY
+0.11
- -
2.07BMarket Cap
Zhejiang Xinguang Pharmaceutical Co., Ltd.
300519.SZ
(Shenzhen Stock Exchange)

Recent

price

12.92

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
2.09
2.24
2.43
2.6
2.36
1.93
1.73
1.83
1.77
1.99
2.2
1.68
1.65
1.66
1.6
Revenue per Share
- -
0.48
0.6
0.88
0.99
0.89
0.66
0.55
0.59
0.62
0.71
0.68
0.4
0.31
0.34
0.35
Basic EPS, GAAP
- -
-0.03
0.42
0.65
0.92
0.74
0.58
0.45
0.52
0.64
0.79
0.69
0.23
0.3
0.41
-0.03
Free Cash Flow per Basic Share
- -
0.18
0.11
0.5
0.5
- -
0.25
0.25
0.3
0.45
0.6
0.6
0.5
0.39
0.3
- -
Dividend per Share
- -
0.74
1.18
1.47
1.86
2.62
3.02
3.28
3.53
3.63
3.65
3.68
3.53
3.38
3.45
3.26
Book Value per Share
- -
1.09
1.6
1.99
2.49
4.72
4.33
4.65
4.95
5.11
5.19
5.31
5.2
5.06
5.2
4.93
Tangible Book Value per Share
- -
120
120
120
120
134
161
160
159
160
161
160
161
163
159
164
Basic Weighted Avg Shares
230
250
268
292
311
315
311
276
291
283
321
351
270
268
265
262
Sales/Revenue/Turnover
18.77
24.87
30.79
40.59
43.27
41.26
37.41
31.45
32.1
33.03
34.51
32.19
18.96
12.84
18.22
13.5
Operating Margin (%)
- -
- -
6
6
6
6
6
8
10
13
13
14
15
15
15
- -
Depreciation Expense
47
57
72
106
119
119
106
88
94
99
114
109
64
50
54
57
Net Income, GAAP
14.78
13.6
14.19
14.07
13.93
14.13
13.36
12.75
13.27
13.78
13.4
13.36
12.03
11.61
14.53
12.11
Effective Tax Rate (%)
20.41
22.75
27.05
36.17
38.14
37.73
34.15
31.85
32.24
34.96
35.62
30.96
23.8
18.83
20.43
21.64
Profit Margin (%)
7
62
123
155
204
522
565
604
648
691
711
724
708
704
723
693
Working Capital
2
2
2
2
2
2
2
2
2
- -
- -
- -
- -
- -
- -
- -
LT Debt
104
142
202
249
309
640
706
753
800
827
846
859
844
831
837
815
Total Equity
- -
31.81
36.44
42.36
39.5
22.92
14.73
10.28
10.35
9.83
11.36
11.3
5.22
3.61
4.92
3.84
Return on Invested Capital (%)
- -
45.36
56.21
64.63
58.38
41.03
25.23
16.32
17.19
17.29
17.11
18.49
11.12
9.03
9.87
10.69
Return on Capital (%)
- -
62.72
62.99
66.36
59.33
41.42
25.37
17.4
17.26
17.33
19.58
18.49
11.12
9.03
9.87
10.69
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
160
160
160
Market Capitalization
2,164
2,238
2,428

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
775
792
751
Cash, Cash Equivalents & STI
688
730
676
Accounts Receivable, Net
12
8
11
Inventories
69
49
62
Total Current Liabilities
71
61
57
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
13.48%
0.25%
0.76%
Free Cash Flow
1.01%
1.94%
35.69%
Net Income, GAAP
-5.99%
-8.86%
7.58%
Sales/Revenue/Turnover
-1.07%
-0.41%
-0.86%
Total Cash Common Dividend
- -
- -
-25%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
101
46
70
51
268
2025
93
48
60
- -
265
2026
88
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.14
- -
- -
- -
0.31
2025
0.15
- -
- -
- -
0.34
2026
0.16
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.39
2025
- -
- -
- -
- -
0.3
2026
- -
- -
- -
- -
- -
Similar Companies
SCYNEXIS, Inc. (SCYX)
Qomel Company Limited (9600.SR)
Radiko Holdings Corp (GEATF)
Jenburkt Pharmaceuticals Limited (JENBURPH.BO)
Shandong Sito Bio-technology Co., Ltd. (300583.SZ)
Lushang Freda Pharmaceutical Co.,Ltd. (600223.SS)
Business
Zhejiang Xinguang Pharmaceutical Co., Ltd. specializes in the research, development, production, and sales of pharmaceutical products, including Chinese patent medicines, chemical medicines, and health food. Its main product categories consist of Chinese patent medicines particularly focused on vascular and trauma diseases; chemical medicines; health food products; and pharmaceutical formulations targeting respiratory, digestive, urinary, pediatric diseases, and immune system enhancement. Prominent products include astragalus extract, stretchant capsules, American ginseng oral solutions, astragalus granules, and supplemental granules. The company targets primarily the Chinese market, with operations headquartered in Shengzhou, China, and was founded in 1998. In the past 1-2 years, Zhejiang Xinguang Pharmaceutical has engaged in strategic expansions including new product launches related to health foods and Chinese patent medicine formulations. Although specific recent acquisitions or partnerships have not been explicitly detailed in public disclosures, the company's operational focus remains centered on expanding its portfolio of proprietary Chinese medicines and chemical drug products. The firm has maintained a strong market presence in China with sustained R&D investment to develop cardiovascular and trauma-related pharmaceutical products. The company is listed on the Shenzhen Stock Exchange (Ticker: 300519.SZ) and continues to emphasize its role within the pharmaceutical and health food industry sectors in China. Its business strategy involves sustainable growth through innovative product development and enhancing its existing product lines in traditional Chinese medicine and chemical pharmaceuticals. Zhejiang Xinguang Pharmaceutical employs over 300 personnel and maintains manufacturing and distribution capabilities mainly within the Chinese domestic market. Overall, Zhejiang Xinguang Pharmaceutical Co., Ltd. operates as a comprehensive pharmaceutical enterprise focusing on traditional Chinese medicine and chemical pharmaceuticals, with recent strategic priorities on expanding product offerings and reinforcing its domestic market footprint. The company’s headquarters is located in Shengzhou, Zhejiang Province. This description reflects its current product portfolio and operational focus along with recent strategic developments as publicly disclosed up to 2025.